Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Volume 323:946-955		October 4, 1990		Number 14

H Buchwald, RL Varco, JP Matts, JM Long, LL Fitch, GS Campbell, MB Pearce, AE Yellin, WA Edmiston, RD Smink, and et al.

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

BACKGROUND AND METHODS. The Program on the Surgical Control of the Hyperlipidemias (POSCH), a randomized clinical trial, was designed to test whether cholesterol lowering induced by the partial ileal bypass operation would favorably affect overall mortality or mortality due to coronary heart disease. The study population consisted of 838 patients (417 in the control group and 421 in the surgery group), both men (90.7 percent) and women, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years. RESULTS. When compared with the control group at five years, the surgery group had a total plasma cholesterol level 23.3 percent lower (4.71 +/- 0.91 vs. 6.14 +/- 0.89 mmol per liter [mean +/- SD]; P less than 0.0001), a low-density lipoprotein cholesterol level 37.7 percent lower (2.68 +/- 0.78 vs. 4.30 +/- 0.89 mmol per liter; P less than 0.0001), and a high-density lipoprotein cholesterol level 4.3 percent higher (1.08 +/- 0.26 vs. 1.04 +/- 0.25 mmol per liter; P = 0.02). Overall mortality and mortality due to coronary heart disease were reduced, but not significantly so (deaths overall [control vs. surgery], 62 vs. 49, P = 0.164; deaths due to coronary disease, 44 vs. 32, P = 0.113). The overall mortality in the surgery subgroup with an ejection fraction greater than or equal to 50 percent was 36 percent lower (control vs. surgery, 39 vs. 24; P = 0.021). The value for two end points combined--death due to coronary heart disease and confirmed nonfatal myocardial infarction--was 35 percent lower in the surgery group (125 vs. 82 events; P less than 0.001). During follow-up, 137 control-group and 52 surgery-group patients underwent coronary-artery bypass grafting (P less than 0.0001). A comparison of base-line coronary arteriograms with those obtained at 3, 5, 7, and 10 years consistently showed less disease progression in the surgery group (P less than 0.001). The most common side effect of partial ileal bypass was diarrhea; others included occasional kidney stones, gallstones, and intestinal obstruction. CONCLUSIONS. Partial ileal bypass produces sustained improvement in the blood lipid patterns of patients who have had a myocardial infarction and reduces their subsequent morbidity due to coronary heart disease. The role of this procedure in the management of hypercholesterolemia remains to be determined. These results provide strong evidence supporting the beneficial effects of lipid modification in the reduction of atherosclerosis progression.

This article has been cited by other articles:

Staels, B., Fonseca, V. A. (2009). Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32: S237-S245 [Full Text]
Robinson, J. G., Wang, S., Smith, B. J., Jacobson, T. A. (2009). Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.. J Am Coll Cardiol 53: 316-322 [Abstract] [Full Text]
Miller, M. E, Kral, J. G (2008). Surgery for obesity in older women. Menopause Int 14: 155-162 [Abstract] [Full Text]
Toutouzas, P., Richter, D. (2008). Carotid Intima--Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial. ANGIOLOGY 59: 77S-79S [Abstract]
Sehayek, E., Hazen, S. L. (2008). Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages. Arterioscler. Thromb. Vasc. Bio. 28: 1296-1297 [Abstract] [Full Text]
Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]
Rippe, J. M., Angelopoulos, T. J., Zukley, L. (2007). The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 10-19 [Abstract]
Denke, M., Pearson, T., McBride, P., Gazzara, R. A, Brady, W. E, Tershakovec, A. M (2006). Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diabetes and Vascular Disease Research 3: 93-102 [Abstract]
Cannon, C. P., Ray, K. K., Braunwald, E. (2006). Reply. J Am Coll Cardiol 48: 852-853 [Full Text]
Crouse, J. R. III (2006). Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art. J. Lipid Res. 47: 1677-1699 [Abstract] [Full Text]
Steinberg, D. (2006). Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it--almost. J. Lipid Res. 47: 1-14 [Abstract] [Full Text]
Robinson, J. G., Smith, B., Maheshwari, N., Schrott, H. (2005). Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis. J Am Coll Cardiol 46: 1855-1862 [Abstract] [Full Text]
Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2005). Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes: Results From the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 46: 1405-1410 [Abstract] [Full Text]
Claudel, T., Staels, B., Kuipers, F. (2005). The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism. Arterioscler. Thromb. Vasc. Bio. 25: 2020-2030 [Abstract] [Full Text]
Roberts, C. K., Barnard, R. J. (2005). Effects of exercise and diet on chronic disease. J. Appl. Physiol. 98: 3-30 [Abstract] [Full Text]
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., Schoelles, K. (2004). Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA 292: 1724-1737 [Abstract] [Full Text]
Sillesen, H. (2004). What does the future hold for the patient with peripheral arterial disease?. Eur Heart J Suppl 6: C43-C48 [Abstract] [Full Text]
Faxon, D. P., Fuster, V., Libby, P., Beckman, J. A., Hiatt, W. R., Thompson, R. W., Topper, J. N., Annex, B. H., Rundback, J. H., Fabunmi, R. P., Robertson, R. M., Loscalzo, J. (2004). Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology. Circulation 109: 2617-2625 [Full Text]
Kroger, K. (2004). Dyslipoproteinemia and Peripheral Arterial Occlusive Disease. ANGIOLOGY 55: 135-138 [Abstract]
Mohler, E. R. III, Hiatt, W. R., Creager, M. A., for the Study Investigators, (2003). Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease. Circulation 108: 1481-1486 [Abstract] [Full Text]
Bhat, B. G., Rapp, S. R., Beaudry, J. A., Napawan, N., Butteiger, D. N., Hall, K. A., Null, C. L., Luo, Y., Keller, B. T. (2003). Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435. J. Lipid Res. 44: 1614-1621 [Abstract] [Full Text]
Binggeli, C., Spieker, L. E., Corti, R., Sudano, I., Stojanovic, V., Hayoz, D., Luscher, T. F., Noll, G. (2003). Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice?. J Am Coll Cardiol 42: 71-77 [Abstract] [Full Text]
Chen, F., Ma, L., Dawson, P. A., Sinal, C. J., Sehayek, E., Gonzalez, F. J., Breslow, J., Ananthanarayanan, M., Shneider, B. L. (2003). Liver Receptor Homologue-1 Mediates Species- and Cell Line-specific Bile Acid-dependent Negative Feedback Regulation of the Apical Sodium-dependent Bile Acid Transporter. J. Biol. Chem. 278: 19909-19916 [Abstract] [Full Text]
Corvol, J.-C., Bouzamondo, A., Sirol, M., Hulot, J.-S., Sanchez, P., Lechat, P. (2003). Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials. Arch Intern Med 163: 669-676 [Abstract] [Full Text]
Hattori, Y., Nakanishi, N., Akimoto, K., Yoshida, M., Kasai, K. (2003). HMG-CoA Reductase Inhibitor Increases GTP Cyclohydrolase I mRNA and Tetrahydrobiopterin in Vascular Endothelial Cells. Arterioscler. Thromb. Vasc. Bio. 23: 176-182 [Abstract] [Full Text]
(2002). References. Circulation 106: 3373-3421 [Full Text]
Di Napoli, P., Taccardi, A.A., Oliver, M., De Caterina, R. (2002). Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 23: 1908-1921
Hirsch, A. T, Gotto, A. M Jr (2002). Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med 7: 323-331 [Abstract]
Charlson, M. E., Allegrante, J. P., McKinley, P. S., Peterson, J. C., Boutin-Foster, C., Ogedegbe, G., Young, C. R. (2002). Improving health behaviors and outcomes after angioplasty: using economic theory to inform intervention. Health Educ Res 17: 606-618 [Abstract] [Full Text]
Elisaf, M., Mikhailidis, D. P. (2002). Statins and Renal Function. ANGIOLOGY 53: 493-502 [Abstract]
DeFranco, A. (2002). Understanding the pathophysiology of the arterial wall: which method should we choose? Intra-vascular ultrasound. Eur Heart J Suppl 4: F29-F40 [Abstract]
Root, C., Smith, C. D., Sundseth, S. S., Pink, H. M., Wilson, J. G., Lewis, M. C. (2002). Ileal bile acid transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. J. Lipid Res. 43: 1320-1330 [Abstract] [Full Text]
Barter, P. J. (2002). Coronary plaque regression: role of low density lipoprotein-apheresis. J Am Coll Cardiol 40: 228-230 [Full Text]
Hornung, R.S. (2002). Reducing cholesterol and atherosclerosis. QJM 95: 339-341 [Full Text]
Kreisberg, R. A., Oberman, A. (2002). Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies. J. Clin. Endocrinol. Metab. 87: 423-437 [Full Text]
Shah, P. K., Kaul, S., Nilsson, J., Cercek, B. (2001). Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I. Circulation 104: 2376-2383 [Full Text]
McGladdery, S. H., Frohlich, J. J. (2001). Lipoprotein lipase and apoE polymorphisms: relationship to hypertriglyceridemia during pregnancy. J. Lipid Res. 42: 1905-1912 [Abstract] [Full Text]
Chen, F., Ma, L., Al-Ansari, N., Shneider, B. (2001). The Role of AP-1 in the Transcriptional Regulation of the Rat Apical Sodium-dependent Bile Acid Transporter. J. Biol. Chem. 276: 38703-38714 [Abstract] [Full Text]
Buchwald, H., Gotto, A. M. Jr, Fuster, V. (2001). Risk Reduction and the Program on the Surgical Control of the Hyperlipidemias Response. Circulation 104 : e47-e47 [Full Text]
Crouse, J. R. III, Furberg, C. D. (2000). Treatment of Dyslipidemia : Room for Improvement?. Arterioscler. Thromb. Vasc. Bio. 20: 2333-2335 [Full Text]
Duane, W. C., Hartich, L. A., Bartman, A. E., Ho, S. B. (2000). Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J. Lipid Res. 41: 1384-1389 [Abstract] [Full Text]
Fodor, J. G., Frohlich, J. J., Genest, J. J.G. Jr., McPherson, P. R., for the Working Group on Hypercholesterolemia and, (2000). Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 162: 1441-1447 [Full Text]
Tsimikas, S., Shortal, B. P., Witztum, J. L., Palinski, W. (2000). In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression. Arterioscler. Thromb. Vasc. Bio. 20: 689-697 [Abstract] [Full Text]
Kelloff, G. J., Sigman, C. C., Johnson, K. M., Boone, C. W., Greenwald, P., Crowell, J. A., Hawk, E. T., Doody, L. A. (2000). Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer. Cancer Epidemiol. Biomarkers Prev. 9: 127-137 [Abstract] [Full Text]
Lee, T. H., Cleeman, J. I., Grundy, S. M., Gillett, C., Pasternak, R. C., Seidman, J., Sennett, C. (2000). Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease. JAMA 283: 94-98 [Abstract] [Full Text]
Ansell, B. J., Watson, K. E., Fogelman, A. M. (1999). An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines. JAMA 282: 2051-2057 [Abstract] [Full Text]
Kleemann, A., Eckert, S., von Eckardstein, A., Lepper, W., Schernikau, U., Gleichmann, U., Hanrath, P., Fleck, E., Neiss, A., Kerber, S., Assmann, G., Breithardt, G., the CLAPT Study Group, (1999). Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT). Eur Heart J 20: 1393-1406 [Abstract]
Campeau, L., Hunninghake, D. B., Knatterud, G. L., White, C. W., Domanski, M., Forman, S. A., Forrester, J. S., Geller, N. L., Gobel, F. L., Herd, J. A., Hoogwerf, B. J., Rosenberg, Y. (1999). Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors : NHLBI Post Coronary Artery Bypass Graft Clinical Trial. Circulation 99: 3241-3247 [Abstract] [Full Text]
Zambon, A., Hokanson, J. E., Brown, B. G., Brunzell, J. D. (1999). Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression : Hepatic Lipase�Mediated Changes in LDL Density. Circulation 99: 1959-1964 [Abstract] [Full Text]
Brier, K. L., Tornow, J. J., Ries, A. J., Weber, M. P., Downs, J. R. (1999). Forecasting Patient Outcomes in the Management of Hyperlipidemia. Arch Intern Med 159: 569-575 [Abstract] [Full Text]
Bucher, H. C., Griffith, L. E., Guyatt, G. H. (1999). Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions. Arterioscler. Thromb. Vasc. Bio. 19: 187-195 [Abstract] [Full Text]
Rabbani, R., Topol, E. J. (1999). Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 41: 402-417 [Abstract] [Full Text]
Mancini, G. B. J., Schulzer, M. (1999). Reporting Risks and Benefits of Therapy by Use of the Concepts of Unqualified Success and Unmitigated Failure : Applications to Highly Cited Trials in Cardiovascular Medicine. Circulation 99: 377-383 [Abstract] [Full Text]
Bustos, C., Hernandez-Presa, M. A., Ortego, M.o., Tunon, J., Ortega, L., Perez, F., Diaz, C., Hernandez, G., Egido, J. (1998). HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057-2064 [Abstract] [Full Text]
Archbold, R A, Timmis, A D (1998). Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. Heart 80: 543-547 [Full Text]
Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., for the Heart and Estrogen/progestin Replacement S, (1998). Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 280: 605-613 [Abstract] [Full Text]
Higaki, J., Hara, S., Takasu, N., Tonda, K., Miyata, K., Shike, T., Nagata, K., Mizui, T. (1998). Inhibition of Ileal Na+/Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits. Arterioscler. Thromb. Vasc. Bio. 18: 1304-1311 [Abstract] [Full Text]
Endres, M., Laufs, U., Huang, Z., Nakamura, T., Huang, P., Moskowitz, M. A., Liao, J. K. (1998). Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 95: 8880-8885 [Abstract] [Full Text]
Lewis, S. J., Sacks, F. M., Mitchell, J. S., East, C., Glasser, S., Kell, S., Letterer, R., Limacher, M., Moye, L. A., Rouleau, J. L., Pfeffer, M. A., Braunwald, E., for the CARE Investigators, (1998). Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 32: 140-146 [Abstract] [Full Text]
Buchwald, H., Varco, R. L., Boen, J. R., Williams, S. E., Hansen, B. J., Campos, C. T., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D. Jr, Sawin, H. S. Jr, for the POSCH Group, (1998). Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH. Arch Intern Med 158: 1253-1261 [Abstract] [Full Text]
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., White, H. (1998). Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis : Results of the LIPID Atherosclerosis Substudy. Circulation 97: 1784-1790 [Abstract] [Full Text]
, (1998). Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97: 1440-1445 [Abstract] [Full Text]
Laufs, U., La Fata, V., Plutzky, J., Liao, J. K. (1998). Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. Circulation 97: 1129-1135 [Abstract] [Full Text]
Grover, S. A., Paquet, S., Levinton, C., Coupal, L., Zowall, H. (1998). Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease: A Comparison of Primary vs Secondary Prevention. Arch Intern Med 158: 655-662 [Abstract] [Full Text]
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., Furberg, C. D. (1998). Cholesterol Reduction Yields Clinical Benefit : Impact of Statin Trials. Circulation 97: 946-952 [Abstract] [Full Text]
Spady, D. K., Cuthbert, J. A., Willard, M. N., Meidell, R. S. (1998). Overexpression of Cholesterol 7alpha -Hydroxylase (CYP7A) in Mice Lacking the Low Density Lipoprotein (LDL) Receptor Gene. LDL TRANSPORT AND PLASMA LDL CONCENTRATIONS ARE REDUCED. J. Biol. Chem. 273: 126-132 [Abstract] [Full Text]
Ichihashi, T., Izawa, M., Miyata, K., Mizui, T., Hirano, K., Takagishi, Y. (1998). Mechanism of Hypocholesterolemic Action of S-8921 in Rats: S-8921 Inhibits Ileal Bile Acid Absorption. J. Pharmacol. Exp. Ther. 284: 43-50 [Abstract] [Full Text]
Sugawara, H., Kubota, I., Tomoike, H., Kubota, I. (1998). Brachial Artery Flow Pattern and Clinical Backgrounds in Patients with Angina Pectoris. ANGIOLOGY 49: 25-31 [Abstract]
Frick, M. H., Syvanne, M., Nieminen, M. S., Kauma, H., Majahalme, S., Virtanen, V., Kesaniemi, Y. A., Pasternack, A., Taskinen, M.-R. (1997). Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol. Circulation 96: 2137-2143 [Abstract] [Full Text]
Mosca, L., Manson, J. E., Sutherland, S. E., Langer, R. D., Manolio, T., Barrett-Connor, E., Barrett-Connor, E. (1997). Cardiovascular Disease in Women : A Statement for Healthcare Professionals From the American Heart Association. Circulation 96: 2468-2482 [Full Text]
Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J., Ockene, I. S., Pearson, T. A., Reed, J., Smith, S. C. Jr, Washington, R. (1997). When to Start Cholesterol-Lowering Therapy in Patients With Coronary Heart Disease : A Statement for Healthcare Professionals From the American Heart Association Task Force on Risk Reduction. Circulation 95: 1683-1685 [Full Text]
Welty, F. K., Mittleman, M. A., Wilson, P. W.F., Sutherland, P. A., Matheney, T. H., Lipinska, I., Muller, J. E., Levy, D., Tofler, G. H. (1997). Hypobetalipoproteinemia Is Associated With Low Levels of Hemostatic Risk Factors in the Framingham Offspring Population. Circulation 95: 825-830 [Abstract] [Full Text]
Andrews, T. C., Raby, K., Barry, J., Naimi, C. L., Allred, E., Ganz, P., Selwyn, A. P. (1997). Effect of Cholesterol Reduction on Myocardial Ischemia in Patients With Coronary Disease. Circulation 95: 324-328 [Abstract] [Full Text]
Frost, P. H., Davis, B. R., Burlando, A. J., Curb, J. D., Guthrie, G. P., Isaacsohn, J. L., Wassertheil-Smoller, S., Wilson, A. C., Stamler, J. (1996). Serum Lipids and Incidence of Coronary Heart Disease: Findings From the Systolic Hypertension in the Elderly Program (SHEP). Circulation 94: 2381-2388 [Abstract] [Full Text]
Waters, D., Lesperance, J., Gladstone, P., Boccuzzi, S. J., Cook, T., Hudgin, R., Krip, G., Higginson, L. (1996). Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 94: 614-621 [Abstract] [Full Text]
Wouter Jukema, J., van Boven, A. J., Zwinderman, A. H., Bal, E. T., Reiber, J. H. C., Bruschke, A. V. G. (1996). The Influence of Angiographic Endpoints on the Outcome of Lipid Intervention Studies: A Proposal for Standardization. ANGIOLOGY 47: 633-642 [Abstract]
Rosenson, R. S. (1996). Beyond Low-Density Lipoprotein Cholesterol: A Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess. Arch Intern Med 156: 1278-1284 [Abstract]
Marchioli, R., Marfisi, R. M., Carinci, F., Tognoni, G. (1996). Meta-analysis, Clinical Trials, and Transferability of Research Results Into Practice: The Case of Cholesterol-Lowering Interventions in the Secondary Prevention of Coronary Heart Disease. Arch Intern Med 156: 1158-1172 [Abstract]
Guetta, V., Cannon, R. O. III (1996). Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women. Circulation 93: 1928-1937 [Full Text]
Gaw, A., Packard, C. J., Lindsay, G. M., Murray, E. F., Griffin, B. A., Caslake, M. J., Colquhoun, I., Wheatley, D. J., Lorimer, A. R., Shepherd, J. (1996). Effects of Colestipol Alone and in Combination With Simvastatin on Apolipoprotein B Metabolism. Arterioscler. Thromb. Vasc. Bio. 16: 236-249 [Abstract] [Full Text]
Corson, J. D., Mohan, C. R., Hoballah, J. J., Sharp, W. J., Kresowik, T. F. (1996). Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?. PERSPECT VASC SURG ENDOVASC THER 9: 75-94
Azen, S. P., Mack, W. J., Cashin-Hemphill, L., LaBree, L., Shircore, A. M., Selzer, R. H., Blankenhorn, D. H., Hodis, H. N. (1996). Progression of Coronary Artery Disease Predicts Clinical Coronary Events : Long-term Follow-up From the Cholesterol Lowering Atherosclerosis Study. Circulation 93: 34-41 [Abstract] [Full Text]
Lacoste, L., Lam, J. Y.T., Hung, J., Letchacovski, G., Solymoss, C. B., Waters, D. (1995). Hyperlipidemia and Coronary Disease : Correction of the Increased Thrombogenic Potential With Cholesterol Reduction. Circulation 92: 3172-3177 [Abstract] [Full Text]
Waters, D., Higginson, L., Gladstone, P., Boccuzzi, S. J., Cook, T., Lesperance, J. (1995). Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women : A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 92: 2404-2410 [Abstract] [Full Text]
Ozaki, Y., Keane, D., Serruys, P. W. (1995). Progression and Regression of Coronary Stenosis in the Long-term Follow-up of Vasospastic Angina. Circulation 92: 2446-2456 [Abstract] [Full Text]
Walsh, J. M. E., Grady, D. (1995). Treatment of Hyperlipidemia in Women. JAMA 274: 1152-1158 [Abstract]
Gould, K. L., Ornish, D., Scherwitz, L., Brown, S., Edens, R. P., Hess, M. J., Mullani, N., Bolomey, L., Dobbs, F., Armstrong, W. T., Merritt, T., Ports, T., Sparler, S., Billings, J. (1995). Changes in Myocardial Perfusion Abnormalities by Positron Emission Tomography After Long-term, Intense Risk Factor Modification. JAMA 274: 894-901 [Abstract]
Gotto, A. M. Jr (1995). Lipid Lowering, Regression, and Coronary Events : A Review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation 92: 646-656 [Full Text]
Mason, J. J., Owens, D. K., Harris, R. A., Cooke, J. P., Hlatky, M. A. (1995). The Role of Coronary Angiography and Coronary Revascularization Before Noncardiac Vascular Surgery. JAMA 273: 1919-1925 [Abstract]
Jukema, J. W., Bruschke, A. V.G., van Boven, A. J., Reiber, J. H.C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J.M., van Rappard, F. M., Lie, K. I. (1995). Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels : The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91: 2528-2540 [Abstract] [Full Text]
Theroux, P. (1995). Angiographic and Clinical Progression in Unstable Angina : From Clinical Observations to Clinical Trials. Circulation 91: 2295-2298 [Full Text]
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., Furberg, C. D. (1995). Cholesterol Reduction Yields Clinical Benefit : A New Look at Old Data. Circulation 91: 2274-2282 [Abstract] [Full Text]
Levine, G. N., Keaney, J. F., Vita, J. A. (1995). Cholesterol Reduction in Cardiovascular Disease -- Clinical Benefits and Possible Mechanisms. NEJM 332: 512-521 [Full Text]
Hebert, P. R., Gaziano, J. M., Hennekens, C. H. (1995). An Overview of Trials of Cholesterol Lowering and Risk of Stroke. Arch Intern Med 155: 50-55 [Abstract]
Weintraub, W. S., Boccuzzi, S. J., Klein, J. L., Kosinski, A. S., King, S. B., Ivanhoe, R., Cedarholm, J. C., Stillabower, M. E., Talley, J. D., DeMaio, S. J., O'Neill, W. W., Frazier, J. E., Cohen-Bernstein, C. L., Robbins, D. C., Brown, C. L., Alexander, R. W., The Lovastatin Restenosis Trial Study Group, (1994). Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty. NEJM 331: 1331-1337 [Abstract] [Full Text]
Insull, W. Jr, Black, D., Dujovne, C., Hosking, J. D., Hunninghake, D., Keilson, L., Knopp, R., McKenney, J., Stein, E., Troendle, A. J., Wright, J. T. Jr (1994). Efficacy and Safety of Once-Daily vs Twice-Daily Dosing With Fluvastatin, a Synthetic Reductase Inhibitor, in Primary Hypercholesterolemia. Arch Intern Med 154: 2449-2455 [Abstract]
Santiago, J. M., Dalen, J. E. (1994). Cholesterol and Violent Behavior. Arch Intern Med 154: 1317-1321 [Abstract]

Comments and questions? Please contact us.